Suche klinische Studie
Weitere Suchoptionen
31 Ergebnis(se)
Rekrutierende Studie = 
; Fortlaufende Studie = 
; Förderung durch ein IRDiRC-Mitglied = 
; ERN-Mitglied = 
Nationale klinische Studie(n)
SPANIEN
Madrid
MADRID
Setmelanotide (RM-493): Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity - ES
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo
SPANIEN
Madrid
MADRID
A Phase 3 trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and AlstrC6m syndrome (AS) Patients with Moderate to Severe Obesity - ES
Hospital Infantil Universitario Niño Jesús
Servicio de Endocrinología, Crecimiento y Metabolismo
VEREINIGTES KONIGREICH
West Midlands
BIRMINGHAM
Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients With Rare Genetic Disorders of Obesity
University Hospital Birmingham
Marshfield Clinic
BELGIEN
OOST-VLAANDEREN
GENT
Phase I Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-CBSB-hRPE65) Gene Vector to Patients With Retinal Disease Due to RPE65 Mutations (Clinical Trials of Gene Therapy for Leber Congenital Amaurosis).
Ghent University Hospital - UZ Gent
Department of Ophthalmology
BELGIEN
OOST-VLAANDEREN
GENT
INSIGHT: An Open-Label, Extension Study to Evaluate the Safety, Tolerability, Efficacy and Pharmacokinetics of QR-110 in Subjects With Leber's Congenital Amaurosis (LCA) Due to the c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene - BE
Ghent University Hospital - UZ Gent
Department of Ophthalmology
BELGIEN
OOST-VLAANDEREN
GENT
ILLUMINATE: Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Systemic Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene - BE
Ghent University Hospital - UZ Gent
Department of Ophthalmology
BELGIEN
OOST-VLAANDEREN
GENT
STELLAR: A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene -BE
Ghent University Hospital - UZ Gent
Department of Ophthalmology
DEUTSCHLAND
Baden-Württemberg
TÜBINGEN
Sicherheit und Wirksamkeit einer einzelnen subretinalen Injektion von rAAV.hCNGA3 bei Patienten mit Achromatopsie bedingt durch Mutationen in CNGA3, untersucht in einer explorativen Studie mit ansteigender Dosierung (RD-Cure Gentherapie-Studie)
Department für Augenheilkunde Tübingen
Universitäts-Augenklinik
DEUTSCHLAND
Baden-Württemberg
TÜBINGEN
ILLUMINATE: Doppelmaskierte, randomisierte, kontrollierte, Multi-Dosis-Studie zur Bewertung von Wirksamkeit, Sicherheit, Verträglichkeit und syst. Exposition von QR-110 bei Amaurosis congenita Leber (LCA) Aufgrund von c.2991+1655A>G-Mutation (p.Cys998X) im CEP290-Gen
Department für Augenheilkunde Tübingen
Universitäts-Augenklinik
DEUTSCHLAND
Nordrhein-Westfalen
BONN
IRIS 2: Behandlung von Blindheit mit dem intelligenten Netzhautimplantatsystem (IRISV2) bei Patienten mit Netzhautdystrophie
Universitäts-Augenklinik Bonn
FRANKREICH
GRAND-EST
STRASBOURG
ILLUMINATE: Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene - FR
CHU de Strasbourg - Hôpital Civil
Centre des Affections Rares en Génétique Ophtalmologique - CARGO
FRANKREICH
ILE-DE-FRANCE
PARIS
A Phase I/IIa Dose Escalation Safety Study of Subretinally Injected SAR422459, Administered to Patients With Stargardt's Macular Degeneration - FR
Centre hospitalier national d'ophtalmologie des Quinze-Vingts
Centre de Référence REFERET
FRANKREICH
ILE-DE-FRANCE
PARIS
ILLUMINATE: Double-masked, Randomized, Controlled, Multiple-dose Study to Evaluate Efficacy, Safety, Tolerability and Syst. Exposure of QR-110 in Leber's Congenital Amaurosis (LCA) Due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene - FR
Centre hospitalier national d'ophtalmologie des Quinze-Vingts
Centre de Référence REFERET
FRANKREICH
ILE-DE-FRANCE
PARIS
STELLAR: A First-in-Human Study to Evaluate the Safety and Tolerability of QR-421a in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene -FR
Centre hospitalier national d'ophtalmologie des Quinze-Vingts
Centre de Référence REFERET
FRANKREICH
PAYS DE LA LOIRE
NANTES
Safety and Efficacy of a Unilateral Subretinal Administration of HORA PDE6B in Patients with Retinitis Pigmentosa Harbouring Mutations in the PDE6B Gene Leading to a Defect in PDE6ß Expression (Phase I-II)
CHU de Nantes - Hôtel Dieu
Centre d'investigation clinique (CIC)
FRANKREICH
PAYS DE LA LOIRE
NANTES
IRIS 2: Compensation for Blindness With the Intelligent Retinal Implant System (IRIS V2) in Patients With Retinal Dystrophy - FR
CHU de Nantes - Hôtel Dieu
Service d'ophtalmologie
ITALIEN
CAMPANIA
NAPOLI
A Safety and Efficacy Study in Subjects with Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE): treatment and follow up of 3 Italian patients
AOU Università degli Studi della Campania "Luigi Vanvitelli"- Cappella Cangiani
U.O.C. di Oculistica
SPANIEN
Cataluña
BARCELONA
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease - ES
Centro Médico Teknon - Grupo Quirónsalud
Servicio de Oftalmología
SPANIEN
Madrid
MADRID
The SeaSTAR Study: A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride with Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease - ES
Hospital Universitario Fundación Jiménez Díaz
Servicio de Genética Clínica
VEREINIGTE STAATEN
Oregon
PORTLAND
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing RPE65 (rAAV2-CB-hRPE65) in Patients With Leber Congenital Amaurosis Type 2 - US
OHSU Doernbecher Children's Hospital -Oregon Health & Science University
Casey Eye Institute
VEREINIGTES KONIGREICH
Greater London
LONDON
VEREINIGTES KONIGREICH
Greater London
LONDON
VEREINIGTES KONIGREICH
Greater London
LONDON
VEREINIGTES KONIGREICH
Greater London
LONDON
A clinical trial of AAV - CNGA3 retinal gene therapy for patients with achromatopsia -GB
Moorfield's Eye Hospital
VEREINIGTES KONIGREICH
Greater London
LONDON
An Open-label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-Associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children with Retinal Dystrophy -GB
Moorfield's Eye Hospital
VEREINIGTES KONIGREICH
Greater London
LONDON
VEREINIGTES KONIGREICH
Greater London
LONDON
An Open-Label Dose Escalation Study of an Adeno-Associated Virus Vector (AAV2/2-hRPE65p-hRPE65) for Gene Therapy of Severe Early-Onset Retinal Degeneration (Phase I-II)
UCL Institute of Ophthalmology
Molecular Therapy
VEREINIGTES KONIGREICH
Greater London
LONDON
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/5-hRKp.RPGR) for Gene Therapy of Adults and Children With X-linked Retinitis Pigmentosa Owing to Defects in Retinitis Pigmentosa GTPase Regulator (RPGR)
University College London - UCL Darwin Building
University College London
VEREINIGTES KONIGREICH
Greater London
LONDON
Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3
University College London - UCL Darwin Building
University College London
Multinationale klinische Studie(n)
NIEDERLANDE
Zuid-Holland
LEIDEN
NIEDERLANDE
Zuid-Holland
LEIDEN